Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C

Digestive and Liver Disease

Volumn 47, Issue 2, 2015, Pages 151-156

  Vukotic, Ranka ^a   Gamal, Nesrine ^a   Andreone, Pietro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiviral therapy; Eligibility; Hepatitis C; Real clinical practice

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; AGE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMORBIDITY; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MENTAL DISORDERS; MIDDLE AGED; MULTICENTER STUDY; PATIENT SELECTION; PHASE 4 CLINICAL TRIAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MENTAL DISORDERS; MIDDLE AGED; PATIENT SELECTION; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; YOUNG ADULT;

EID: 84921293101     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.11.002     Document Type: Article

References (18)

1. Cornberg M., Razavi H.A., Alberti A., et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International 2011, 31(Suppl. 2):30-60.
2. Ciccozzi M., Lo Presti A., Ciccaglione A.R., et al. Phylogeny and phylodinamic of Hepatitis C in Italy. BMC Infectious Diseases 2012, 12(Suppl. 2):S5.
3. Adam R., Karam V., Delvart V., et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). All contributing centers (www.eltr.org); European Liver and Intestine Transplant Association (ELITA). Journal of Hepatology 2012, 57:675-688.
4. Deuffic-Burban S., Deltenre P., Buti M., et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012, 143:974-985.
5. Pearlman B.L. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infectious Diseases 2012, 12:717-728.
6. daCosta DiBonaventura M., Yuan Y., Wagner J.S., et al. The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes. European Journal of Gastroenterology and Hepatology 2012, 24:869-877.
7. Vietri J., Prajapati G., El Khoury A.C. The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gastroenterology 2013, 17:13-16.
8. Guadagnino V., Stroffolini T., Rapicetta M., et al. Prevalence, risk factors and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in a southern Italy. Hepatology 1997, 26:1006-1011.
9. Guadagnino V., Stroffolini T., Caroleo B., et al. Hepatitis C virus infection in an endemic area of southern Italy 14 years later: evidence for a vanishing infection. Digestive and Liver Disease 2013, 45:403-407.
10. Montenegro L., De Michina A., Misciagna G., et al. Virus C hepatitis and type 2 diabetes: a cohort study in southern Italy. American Journal of Gastroenterology 2013, 108:1108-1111.
11. Papadopoulos N., Manolakopoulos S., Deutsch M., et al. Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece. European Journal of Gastroenterology and Hepatology 2013, 25:587-593.
12. Gramenzi A., Conti F., Cammà C., et al. Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver. AISF HepaElder Study Group. Digestive and Liver Disease 2012, 44:674-680.
13. Sublette V.A., Douglas M.W., McCaffery K., et al. Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review. Liver International 2013, 33:894-903.
14. Melia M.T., Muir A.J., McCone J., et al. Racial differences in hepatitis C treatment eligibility. Hepatology 2011, 54:70-78.
15. Marcellin P., Chousterman M., Fontanges T., et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver International 2011, 31:516-524.
16. Carrión J.A., Gonzalez-Colominas E., García-Retortillo M., et al. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. Journal of Hepatology 2013, 59:926-933.
17. Bourlière M., Ouzan D., Rosenheim M., et al. Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007). Antiviral Therapy 2012, 17:101-110.
18. European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C 2014. Journal of Hepatology 2014, 61:373-395.